Safety data, including from LTE
Visit the website to learn more. U.S. Full Prescribing Information | Important Safety Information . . . INDICATION SOTYKTU® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants. Explore the safety […]
Efficacy data from LTE
Visit the website to learn more. U.S. Full Prescribing Information | Important Safety Information . . . INDICATION SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants. SELECT IMPORTANT SAFETY INFORMATION […]
PASI 90 and Scalp Data
Visit the website to learn more. U.S. Full Prescribing Information | Important Safety Information . . . INDICATION SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants. SOTYKTU showed superior […]
HF Guidelines
TK Prescribing Information and Medication Guide JARDIANCE is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. JARDIANCE is not recommended: to […]
Clinical Results in Adults with Heart Failure
TK Prescribing Information and Medication Guide JARDIANCE is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. JARDIANCE is not recommended: to […]
Safety Information for JARDIANCE
TK Prescribing Information and Medication Guide JARDIANCE is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. JARDIANCE is not recommended: to […]
APP JARDIANCE Patient Education Tool
The DUPIXENT Profile
TK Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc. Important Safety Information Full Prescribing Information INDICATION DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients […]
Efficacy and Safety Profile
Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc. Important Safety Information Full Prescribing Information INDICATION DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies […]
Appropriate Patients
Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc. Important Safety Information Full Prescribing Information INDICATION DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies […]